- Active, not recruiting
NCT05000450: Phase 1/2: Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell RRMM
Updated: Feb 10
IGNITE STUDY - ALLO-605: IGNITE STUDY UTILIZING FIRST TurboCAR™ TO TARGET BCMA
NCT05000450: Phase 1/2: Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
The purpose of the ALLO-605-201 study is to assess the safety, efficacy, and cell kinetics of ALLO605 in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647.
Sponsor
Locations
United States, Colorado
United States, Texas
ClinicalTrials.gov Identifier: NCT05000450
Official Title: A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-647 and ALLO-605, an Anti- BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
First Posted : August 11, 2021
Click here to see details on ClinicalTrials.gov
Genetic: ALLO-605
Biological: ALLO-647
Drug: Fludarabine
Drug: Cyclophosphamide
Allogeneic Anti-BCMA CAR T Cells ALLO-605 (Code C182066)
ALLO 605
ALLO-605
ALLO605
Allogeneic Anti-BCMA CAR T Cells ALLO-605
Allogeneic Anti-BCMA CAR-T Cells ALLO-605
Allogeneic Anti-BCMA TRAC/CD52-edited CAR T Cells ALLO-605
Allogeneic BCMA TurboCAR T Cells ALLO-605
Anti-CD52 Monoclonal Antibody ALLO-647 (Code C160787)
ALLO 647
ALLO-647
ALLO647
Anti-CD52 Monoclonal Antibody ALLO-647
Locations
United States, Colorado
United States, Texas